Bayer and Aignostics to collaborate on next generation precision oncology

"Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare"

18-Mar-2024 - Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, ...

Bayer to partner with Twist Bioscience to accelerate drug discovery

Twist Bioscience eligible to receive up to USD 188 million

06-Oct-2023 - Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company’s “Library of Libraries”, a collection of synthetic antibody libraries that harness innovative ...

Bayer to Accelerate Drug Discovery with Google Cloud’s High-Performance Compute Power

12-Jan-2023 - Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud’s Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run cutting-edge machine learning models and computationally-intensive workloads, to help accelerate ...